ivyhofy.wordpress.com
Under the terms of the license and supply agreementd announced in July GSK (NYSE: GSK) will make payments contingent upon successfukl milestone achievements and will pay royalties to Antigenics on net sales for a period of at least 10 years after the vaccine’s first commercia sale. Antigenics said recent Phase 2 malariaq studiesshowed that, over an eight-month follow-up its so-called RTS,S component reduced clinical episodes of malariz by 53 percent and had a promising safetyy and tolerability profile when used alongside standard infant vaccines. If results of the Phases 3 studyare positive, GSK plans to submift applications for regulatory approval in 2011.
If RTS,S could be introducedc in 2012 for babies aged 5 monthd to17 months. GSK officials said if the drug is approveds for use in infants and recommended by international and Africanbhealth organizations, the company coul d make the vaccine more widely available by 2014. Investoras responded positively tothe news, buoyingb Antigenic’s (NASDAQ: AGEN) stock over 8 percent in mornin g trading Wednesday to $2.10 a up from $1.94 at the previous day’ws close.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment